Visionary Wealth Advisors Acquires Shares of 89,793 Danaher Corporation $DHR

Visionary Wealth Advisors bought a new position in shares of Danaher Corporation (NYSE:DHR) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 89,793 shares of the conglomerate’s stock, valued at approximately $64,655,000. Danaher accounts for about 2.6% of Visionary Wealth Advisors’ holdings, making the stock its 9th largest position.

A number of other large investors have also recently modified their holdings of DHR. EP Wealth Advisors LLC bought a new position in Danaher in the second quarter valued at about $3,807,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Danaher by 303.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock worth $56,777,000 after acquiring an additional 186,584 shares during the last quarter. Puzo Michael J acquired a new stake in shares of Danaher in the 2nd quarter valued at approximately $8,624,000. Legal & General Group Plc grew its holdings in shares of Danaher by 1.0% during the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock valued at $1,029,061,000 after purchasing an additional 43,169 shares during the last quarter. Finally, Madison Asset Management LLC bought a new stake in shares of Danaher during the 2nd quarter valued at approximately $85,451,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on DHR. Piper Sandler assumed coverage on shares of Danaher in a research note on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price objective for the company. Evercore reaffirmed an “outperform” rating and set a $230.00 target price on shares of Danaher in a research note on Monday, July 6th. TD Cowen lowered their price target on shares of Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Citigroup assumed coverage on Danaher in a research note on Tuesday, May 26th. They issued a “buy” rating and a $230.00 price target for the company. Finally, Wolfe Research lowered Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $228.91.

Danaher Trading Down 1.7%

DHR opened at $215.18 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company’s 50 day moving average price is $196.49 and its two-hundred day moving average price is $192.39. The firm has a market capitalization of $151.27 billion, a price-to-earnings ratio of 38.22, a PEG ratio of 2.72 and a beta of 0.78.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.77 earnings per share. As a group, research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.